LLP2A-bisphosphonate conjugates for osteoporosis treatment
US9119884B2 · kind B2 · utility
3Cited by
3References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2012 |
| Grant date | Sep 1, 2015 |
| Priority date | — |
| Expiry date | Jan 19, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.